Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894803 · ClinicalTrials.gov registry record · Phase 2
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT00894803 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 126 participants.
The verdict
NCT00894803, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.
Interventions
- DRUG rt-PA
- DRUG Eptifibatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00894803
The ClinicalTrials.gov registry entry for NCT00894803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rt-PA is the first listed.
NCT00894803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00894803 about?
NCT00894803 is a clinical study titled "Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke". The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.
What is the current status of trial NCT00894803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2009-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00894803?
The interventions under investigation include: rt-PA (DRUG), Eptifibatide (DRUG).
Who is sponsoring clinical trial NCT00894803?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.